中文摘要：

目的 探讨长效利培酮微球（RLAI）、利培酮片、喹硫平片治疗精神分裂症的临床疗效、安全性及对患者社会功能的影响.方法 将120例精神分裂症患者随机分为3组,RLAI组30例,利培酮片组45例,喹硫平片组45例,治疗12周.采用阳性与阴性症状量表（PANSS）、个人和社会功能量表（PSP）及副反应量表（TESS）分别评定临床疗效、社会功能及不良反应.结果 治疗8周、12周末RLAI组阳性与阴性症状量表评分显著低于利培酮组和喹硫平组,个人和社会功能量表评分显著高于利培酮片和喹硫平组（P＜0.01）;治疗12周末,3组临床疗效比较差异无显著性（P＞0.05）;RLAI与利培酮片组主要不良反应为震颤、静坐不能,喹硫平组为体重增加、心动过速.结论 注射用利培酮微球与口服利培酮片、喹硫平片治疗精神分裂症的疗效相当,但RLAI组在控制精神症状、改善社会功能方面优于口服利培酮片、喹硫平片,且有长期维持治疗的优势.

英文摘要：

Objective To investigate the clinical efficacy, safety and the influence of the social function among risperi- done long-acting microsphere （RLAI）, risperidone and quetiapine pills for the treatment of schizophrenia patients. Methods A total of 120 cases of patients with schizophrenia were randomly divided into 3 groups, RLAI group of 30 cases, risperidone group of 45 cases, quetiapine group of 45 cases, treated for 12 weeks. Clinical efficacy was assessed with the Positive and Negative Syndrome Scale （PANSS）, social functions with the Personal and Social Performance Scale （PSP） and adverse reactions with the Treatment Emergent Symptom Scale（TESS）. Results The PANSS scores were significantly lower and PSP scores were significantly higher （P〈0.01） in RLAI than risperidone and quetiapine group at the end of 8th and 12th week; There were no significant differences in efficacy among three groups （P〉0.05） at 12th weekend; Main adverse reactions of RLAI and risperidone were tremor, akathisia, those of quetiapine group were weight gain and tachycardia. Conclusion RLAI, risperidone and quetiapine have equivalent difficancy in the treatment of schizophrenia, but RLAI has an advantage in controlling mental symptoms, improve social function over risperidone and quetiapine pills, and RLAI has the advantage of long-term maintenance treatment.